Study protocol
Study theme · illustration
Study protocol: planned research, not a report of completed treatment outcomes.

Who was studied?

Patients with borderline resectable or unresectable locally advanced pancreatic ductal adenocarcinoma.

What does the publication report?

Phase I evaluates radiation dose and safety; phase II plans to evaluate one-year OS and resection-related outcomes.

Safety findings

Safety and tolerability are phase I objectives; this protocol has no completed safety results.

How should we interpret it?

This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study · DOI: 10.1177/15330338251399255 · PMID: 41252443

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.